Agilum has supplied NYU Langone Health and more than 45 other NY health systems – 21% percent of all hospitals in New York state – with the real-world data and analytics methodologies to track, analyze, and predict drug utilization data in real-time during the course of the COVID-19 crisis.
Agilum Healthcare Intelligence’s Chief Medical Information Officer, William Kirsh, DO, MPH, has recorded a virtual HIMSS presentation, “Evolving Formulary Decision-Making with Real-World Data.”
Agilum Healthcare Intelligence’s CEO, Travis Leonardi and CMIO, William Kirsh, DO, M.P.H. were featured guests on a recent podcast titled, “Your Patient Data.”
Agilum’s proprietary Comparative Rapid Cycle Analytics™ (CRCA) platform provided both the analytics and data necessary to help NYU Langone Health evaluate the effectiveness of intravenous acetaminophen (IV APAP) for common orthopedic surgeries. This inaugural study provided answers that not only had the power to influence the formulary assessment, they also served as the basis for a peer-reviewed study published in Hospital Pharmacy this past week.
A new feature article in ASHP highlights the importance of real-world data (RWD) to help predict drug demand for the treatment of COVID-19. Hospitals are facing serious challenges as they adapt to the unpredictable disruption of the drug supply chain, and Agilum’s real-world data is enabling them to tackle drug supply issues before they affect patient care.
Agilum’s Chief Executive Officer, Travis Leonardi, RPh, CP, and Chief Medical Information Officer, William Kirsh, DO, MPH, have been featured in Pharmaceutical Executive. The article discusses the challenges of clinical trials during the current COVID-19 pandemic and highlights Agilum’s work to provide real-world data regarding patient drug regimens and survival rates.
Agilum’s Chief Executive Officer, Travis Leonardi, and Chief Medical Information Officer, Dr. William Kirsh, have been featured in South Florida Business & Wealth. The article highlights Agilum’s work to provide real-world data regarding drug regimens and survival rates for COVID-19 patients.
A feature article in the Washington Examiner reveals that NYU Langone Health has helped identify a “blueprint for coronavirus treatments” by analyzing Agilum’s real-world data on COVID-19 patients’ drug regimens and survival rates.
When it comes to hospitals deciding which medications to select for formulary addition and which will remain on the formularies, the method is largely static and antiquated, having changed very little since the 1990s.